We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+50.65%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$5.42B
AUM Growth
+$1.85B
(+52%)
Cap. Flow
+$509M
Cap. Flow
% of AUM
9.4%
Top 10 Holdings %
Top 10 Hldgs %
46.89%
Holding
89
New
20
Increased
11
Reduced
36
Closed
9
Avg Time Held
1.2
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADC Therapeutics
ADCT
|
+$210M |
| 2 |
BioNTech
BNTX
|
+$145M |
| 3 |
IMMU
Immunomedics Inc
IMMU
|
+$102M |
| 4 |
Pliant Therapeutics
PLRX
|
+$90.5M |
| 5 |
Repare Therapeutics
RPTX
|
+$76.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$128M |
| 2 |
uniQure
QURE
|
+$90.1M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$75.7M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$56.7M |
| 5 |
Centene
CNC
|
+$49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.59% |
| 2 | Industrials | 1.02% |
| 3 | Financials | 0.23% |
| 4 | Miscellaneous | 0.16% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $2.26M | 0.04% |
21,229
| – | – |
2016 Q2
16 quarters
|
|
|
VAPO
77
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $1.02M | 0.02% |
3,125
| – | – |
2018 Q4
6 quarters
|
|
78
Ovid Therapeutics
OVID
$441M
| $899K | 0.02% |
121,950
| – | – |
2017 Q2
12 quarters
|
|
|
ELGX
79
DELISTED
Endologix Inc
ELGX
| $63K | ﹤0.01% |
78,755
| – | – |
2015 Q4
18 quarters
|
|
|
CSLT
80
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $8K | ﹤0.01% |
10,229
| – | – |
2018 Q2
8 quarters
|
|
81
Adaptive Biotechnologies
ADPT
$4.08B
| – | – |
-414,400
| Closed | -$11.5M | – |
|
|
82
Centene
CNC
$34.8B
| – | – |
-824,090
| Closed | -$49M | – |
|
83
Crescent Biopharma
CBIO
$464M
| – | – |
-2,535
| Closed | -$578K | – |
|
84
Gossamer Bio
GOSS
$54.4M
| – | – |
-3,246
| Closed | -$2.64M | – |
|
85
Revolution Medicines
RVMD
$40.6B
| – | – |
-303,371
| Closed | -$6.65M | – |
|
|
86
Tandem Diabetes Care
TNDM
$1.15B
| – | – |
-881,266
| Closed | -$56.7M | – |
|
87
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| – | – |
-557,800
| Closed | -$18.5M | – |
|
|
SGEN
88
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-655,700
| Closed | -$75.7M | – |
|
|
CLVS
89
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-99,485
| Closed | -$633K | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q2 2020 Portfolio in Review
As of Q2 2020, Redmile Group held 89 positions worth $5.42B, up 52% from $3.57B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Redmile Group deployed $509M of net new capital in Q2 2020, opening 20 new positions and adding to 11 existing holdings. Its largest new stake was ADC Therapeutics: 5,525,870 shares worth $259M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Biogen, an estimated $128M trimmed.
- Redmile Group's largest Q2 2020 buy was ADC Therapeutics: 5,525,870 shares worth $259M.
- Redmile Group added most to BioNTech in Q2 2020, an estimated $145M increase.
- Redmile Group's biggest Q2 2020 reduction was Biogen, cutting an estimated $128M.
- Redmile Group fully exited Seagen Inc. Common Stock in Q2 2020, selling an estimated $75.7M.
- Redmile Group's ten largest holdings make up 47% of its $5.42B portfolio in Q2 2020.
- Redmile Group opened 20 new positions and closed 9 in Q2 2020.
- Redmile Group's portfolio value rose 52% quarter-over-quarter to $5.42B.
Based on Redmile Group's 13F filing for Q2 2020, filed 14 Aug 2020.